Emerging Markets At Stake As Viehbacher Departs Sanofi?
This article was originally published in PharmAsia News
As emerging markets represent 32% of Sanofi’s overall sales, the highest among big pharma firms, will the sudden departure of Viehbacher leave a dent in one of the firm’s key growth platforms?
You may also be interested in...
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.